Previous Article | Next Article ![]()
Journal of Clinical Microbiology, September 2008, p. 3021-3027, Vol. 46, No. 9
0095-1137/08/$08.00+0 doi:10.1128/JCM.00689-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Centre for Infectious Diseases and Microbiology,1 Westmead Millennium Institute, University of Sydney,2 Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, Sydney West Area Health Service, Westmead,3 AusDiagnostics Pty. Ltd., 3/36 O'Riordan St., Alexandria, New South Wales, Australia4
Received 11 April 2008/ Returned for modification 18 June 2008/ Accepted 5 July 2008
|
|
|---|
(EF1-
), and β-tubulin genes to identify 11 fungal pathogens: Candida albicans, Candida dubliniensis, Candida glabrata, Candida guilliermondii, Candida krusei, Candida parapsilosis complex, Candida tropicalis, Cryptococcus neoformans complex, Fusarium solani, Fusarium species, and Scedosporium prolificans. The presence or absence of a fungal target was confirmed by melting curve analysis. Identification by MT-PCR correlated with culture-based identification for 44 (100%) patients. No cross-reactivity was detected in 200 blood culture specimens that contained bacteria or in 30 blood cultures without microorganisms. Fungi were correctly identified in five specimens with bacterial coinfection and in blood culture samples that were seeded with a mixture of yeast cells. The MT-PCR assay was able to provide rapid (<2 h), sensitive, and specific simultaneous detection and identification of fungal pathogens directly from blood culture specimens. |
|
|---|
Rapid identification of fungal pathogens in blood is essential for patient management. However, diagnosis is often delayed because current laboratory practices are laborious and slow. The "gold standard" for detection of fungemia is blood culture, which is slow (requiring at least 48 to 96 h to achieve species identification) and insensitive and fails to detect yeasts in up to 65% of patients (6). Furthermore, a period of 5 to 7 days is required to reliably declare a specimen negative (31, 38).
Numerous strategies for more rapid identification of fungal pathogens from blood cultures have been described. These include single-target and multiplex PCR assays which have used electrophoretic migration, DNA sequencing, or fluorescent probe hybridization for fungal identification (7, 8, 22, 30, 34, 39, 40). While these assays have shown promise in diagnosing fungal infections, there are problems that prevent their routine use in clinical laboratories. For example, the use of multiple fluorescent probes is expensive, size differentiation by gel electrophoresis does not provide real-time analysis, and DNA sequence analysis is time-consuming and expensive and cannot detect mixed fungemia. Multiplex tandem PCR (MT-PCR), on the other hand, is a simple, rapid, real-time assay that can provide a sensitive alternative for the simultaneous detection and identification of numerous pathogens (up to 72 targets) directly from clinical specimens (44).
We describe the development and evaluation of a novel, rapid MT-PCR assay for the detection and identification of fungi directly from positive blood cultures. The assay identifies seven Candida species (C. albicans, C. dubliniensis, C. glabrata, C. guilliermondii, C. krusei, C. parapsilosis complex, and C. tropicalis), Cryptococcus neoformans complex, Fusarium solani, Fusarium sp., and S. prolificans. Target species were selected based on their (i) expected frequency of recovery from blood culture, (ii) potential resistance to commonly administered antifungals, and (iii) clinical importance. We targeted sequence-variable regions of the multicopy ribosomal DNA complex (internal transcribed spacer 1 [ITS1] and ITS2) (23) and the elongation factor 1-
(EF1-
) (14) and β-tubulin (17) genes. The MT-PCR assay results were correlated with those obtained by culture.
|
|
|---|
|
View this table: [in a new window] |
TABLE 1. Fungal, bacterial, and parasitic strains used to evaluate the MT-PCR assay
|
Total nucleic acid extraction. Nucleic acid was extracted in a class II laminar-flow cabinet with the nucliSENS easyMAG instrument (BioMérieux, Baulkham Hills, New South Wales, Australia) as follows.
(i) Microbial cultures. Two-milliliter suspensions of a 0.5 McFarland standard were prepared from pure cultures. For fungal DNA extraction, suspensions were centrifuged at 16,000 x g for 10 min and the supernatant was removed. The pellet was resuspended in 200 µl molecular biology grade water (Sigma-Aldrich, Castle Hill, New South Wales, Australia) containing 50 U lyticase (Sigma-Aldrich) and incubated at 37°C for 1 h. The suspension was transferred to the nucliSENS easyMAG instrument for DNA isolation according to the manufacturer's instructions. DNA was isolated directly from the bacterial and parasite suspensions with the nucliSENS easyMAG instrument. The elution volume selected for all microbial DNA extractions was 110 µl.
(ii) Blood culture specimens. DNA was extracted from blood culture media (100 µl) as previously described (39), with some modifications. Briefly, after washes in alkali wash solution (0.5 M NaOH, 0.05 M trisodium citrate dehydrate) (27) and phosphate-buffered saline (0.137 M NaCl, 3 mM KCl, 8 mM Na2HPO4), the pellet was resuspended in 200 µl molecular biology grade water containing 50 U lyticase and incubated at 37°C for 1 h and at 95°C for 10 min. The suspension was then transferred to the nucliSENS easyMAG instrument for DNA isolation. The elution volume selected was 60 µl.
Primer design.
To ensure accuracy and reproducibility and to identify possible intraspecies variation, consensus sequences were generated from available GenBank sequences with BioEdit (18) and CLUSTAL_W (http://www.ebi.ac.uk/Tools/clustalw2/). Consensus sequences from different species were aligned with CLUSTAL_W to identify variable regions suitable for species specific identification. Primers were designed with AusDiagnostics Pty. Ltd. (Alexandria, New South Wales, Australia) software (http://www.ausdiagnostics.com/qilan/AusPrimerDesign.jsp). The ITS1 and ITS2 regions, EF1-
, and β-tubulin genes were used to design specific primers targeting C. albicans, C. dubliniensis, C. glabrata, C. guilliermondii, C. krusei, C. parapsilosis, C. tropicalis, C. neoformans, F. solani, Fusarium sp., and S. prolificans. Primer sequences are not shown due to commercial confidentiality agreements with AusDiagnostics Pty. Ltd. (Table 2). Where possible, inner amplicons were restricted to 70 to 100 bp and outer amplicons were restricted to <200 bp. Primer pairs were rejected if they did not produce the correct-size product on a Bioanalyzer DNA separation chip (Agilent Technologies, Forest Hill, Victoria, Australia). The theoretical specificities of all primer sequences were tested with the Basic Local Alignment Search Tool (BLAST; http://www.ncbi.nlm.nih.gov/blast/Blast.cgi).
|
View this table: [in a new window] |
TABLE 2. MT-PCR gene targets, amplicon sizes, and expected melting temperatures for species identificationa
|
(i) First-round multiplexed preamplification. PCRs were performed in a 20-µl volume consisting of 10 µl step 1 mastermix (composition is commercial in confidence; Corbett Research, Mortlake, New South Wales, Australia), 7 µl molecular biology grade water, 1 U MangoTaq DNA polymerase (Bioline, Alexandria, New South Wales, Australia) containing 20 U Moloney murine leukemia virus reverse transcriptase (Invitrogen, Mt. Waverly, Victoria, Australia), and 2 µl template DNA. Amplification was performed on a RotorGene thermal cycler (RG6000; Corbett Research). Thermal cycling conditions were 55°C for 2 min and 95°C for 5 min, followed by 10 cycles of 95°C for 10 s, 60°C for 20 s, and 72°C for 20 s.
(ii) Second-round quantification amplification. Four microliters of each multiplexed amplification product was diluted into 150 µl step 2 mastermix (composition commercial in confidence; Corbett Research), 138.4 µl molecular biology grade water, and 7.6 U MangoTaq DNA polymerase. A 20-µl aliquot was then added to the corresponding 12 positions on the gene disc containing the lyophilized inner primers. Amplification was performed on the RG6000 thermal cycler. Thermal cycling conditions were 55°C for 2 min, followed by 30 cycles of 95°C for 1 s, 60°C for 10 s, and 72°C for 10 s. Fluorescence was measured at the end of each 72°C extension step. Following cycling, a melting curve was generated from 72 to 95°C at 0.5°C intervals. The expected melting temperature of each fungal target was established from pure culture DNA (Table 2). The presence or absence of an organism was determined by analysis software (AusDiagnostics) which compared the given melting temperature to the expected melting temperature. An internal positive control was included for each specimen to monitor for PCR inhibition.
Assay detection limit. To determine the MT-PCR detection limit for fungal cells extracted from whole blood, serial dilutions of C. albicans (104 to 1 CFU/ml) were seeded into blood obtained from healthy donors, in triplicate. Yeast cell numbers were confirmed by plating dilutions onto Sabouraud dextrose agar (Difco) and counting colonies following 2 days of incubation at 30°C. DNA was extracted and subjected to MT-PCR (see above).
|
|
|---|
Detection limit and reproducibility. The detection limit of the assay was tested in triplicate by inoculating serial dilutions of C. albicans into blood obtained from healthy individuals. The detection limit was 10 CFU/ml blood, equivalent to 0.33 cell per PCR (Fig. 1).
![]() View larger version (17K): [in a new window] |
FIG. 1. Cycling curve produced from blood samples seeded with serial dilutions of C. albicans, showing the detection limit of MT-PCR (CFU/ml). The positive control (+ve) indicates that the assay was not inhibited.
|
![]() View larger version (19K): [in a new window] |
FIG. 2. Melting curves generated from a mixture of 49 different DNA templates (Table 1) illustrating the melting peaks obtained from the 12 MT-PCR targets: C. albicans (Ca), C. dubliniensis (Cd), C. glabrata (Cg), C. guilliermondii (Cgu), C. krusei (Ck), C. parapsilosis (Cp), C. tropicalis (Ct), C. neoformans (Cn), F. solani (Fs), Fusarium sp. (Fsp), S. prolificans (Sp), and a positive control (+ve). deg, degrees; dF/dT, derivative of fluorescence with respect to temperature.
|
![]() View larger version (15K): [in a new window] |
FIG. 3. Melting curves generated from blood cultures seeded with C. albicans and C. glabrata (a) and with C. parapsilosis and C. krusei (b). The melting temperatures determined were compared to the expected melting temperatures (Table 2) by automated analysis software to determine the presence or absence of an organism. +ve, positive control; deg, degrees; dF/dT, derivative of fluorescence with respect to temperature.
|
|
View this table: [in a new window] |
TABLE 3. Results of culture and MT-PCR analysis of blood culture specimens
|
Five samples (specimens 10, 19A, 25, 32, and 33) showed that fungal identification was not inhibited in the presence of bacterial coinfection. No cross-reactivity was detected in 200 control blood culture specimens that were positive for bacteria, 30 negative blood cultures, or broth from a subset of uninoculated blood culture bottles.
|
|
|---|
The clinical applicability of the assay was confirmed by testing 70 blood culture specimens from 44 patients that were positive for yeast by Gram staining. Results concordant between culture and MT-PCR were achieved for 42 patients for which there was a detection target (Table 3). For patients 25 and 38, no MT-PCR result was obtained due to the absence of a detection target for C. nivariensis, K. ohmeri, and C. lambica on the assay. All three organisms are uncommon causes of candidemia. In an Australian survey of candidemic episodes, only one isolate of C. lambica was identified from 1,095 cases over a 4-year period (9). Similarly, there have been few reports documenting fungemia due to K. ohmeri (4, 19, 20, 33, 41, 45) and C. nivariensis (1, 5, 16). Targets for these organisms can be added to the MT-PCR in the future if there are increasing reports of their causing candidemia.
Polycandidal infections were observed in 2.2% of the cases surveyed in the Australian Candidemia Study (9). To simulate such episodes and demonstrate the specific and multiplex capability of the MT-PCR platform, blood cultures were spiked with two or more Candida species and each species was identified (Fig. 3a and b). Furthermore, specificity of fungal identification was maintained in the presence of bacterial coinfection (specimens 10, 19A, 25, 32, and 33).
The choice of species targeted and configuration of the assay were determined by the frequency with which various Candida species are recovered from blood, likely resistance to commonly administered antifungal drugs (C. glabrata, C. krusei, Fusarium species, and S. prolificans), and a high probability of early death (S. prolificans). Although no cases of Fusarium or S. prolificans infection were observed in this study, there have been increasing reports highlighting the significant need for the rapid identification of these molds from blood culture (3, 32, 36, 42). Aspergillus species were not included as a target in this assay because they are rarely cultured from blood (10).
The fungal MT-PCR assay has demonstrated high levels of sensitivity (10 cells/ml blood) and specificity. For primer design, it was important to consider the quality of the input sequence, as GenBank sequence submissions are not peer reviewed and it has been estimated that 10 to 20% of the fungal sequences in GenBank have been misidentified (26). Therefore, primers were designed from consensus sequences generated in regions devoid of intraspecies variability.
The "nested" feature of the MT-PCR also contributed to the high level of specificity, as it depended on two different sets of specific primers for both rounds of amplification. This differs from other published assays, which have only provided one level of specificity by combining panfungal amplification and species-specific primers (7), probes (40), or product size differentiation (8, 30) for fungal identification. Manipulation of post-PCR products always carries the potential for contamination. However, MT-PCR is not like a nested PCR assay since the first-step multiplex PCR is not run to completion and serves only as a preamplification process. Only 10 cycles of amplification were used in step 1, and at this stage of a PCR, undetectable amounts of product are made. To date, we have observed no case of cross-contamination.
The fungal MT-PCR offers further advantages over traditional multiplex assays because it is a real-time test and uses automated software analysis to determine the presence or absence of an organism. Unlike classical multiplex assays, where inhibition due to competition between primers is inevitable, MT-PCR incorporates two separate steps for multiplexing and quantification. Competition between primers in the first-step multiplex assay is avoided, as DNA is only amplified for a limited number of cycles (10 cycles), at which point the amount of deoxynucleoside triphosphates and primers is not limiting. Carryover of primers from the first step to the quantification PCR is also negligible since the first-round product is diluted 50-fold (44). This prevents the step 1 primers from taking part in the step 2 reaction and avoids problems with PCR inhibition. The inclusion of an internal positive control for each specimen monitors for PCR inhibition.
The MT-PCR process is simple, and a robot for automated operation (AusDiagnostics Pty. Ltd.) is available so that the platform can be operated by laboratory staff without molecular test experience. Furthermore, this assay utilizes SYBR green technology, so expensive probes are not required. Altogether, the MT-PCR assay is a rapid and cost-effective platform, requiring <4 h for the whole procedure (DNA extraction, MT-PCR, and analysis), and has costs similar to those of current routine laboratory tests.
In conclusion, this study illustrates the potential benefits of using fungal MT-PCR for the sensitive and specific identification of fungal pathogens from blood culture specimens. The assay has the advantage of accurate and simultaneous identification of microbial infections. It is envisaged that the assay will provide a major advantage in the routine diagnostic laboratory by providing faster identification, leading to prompt initiation of targeted therapy and better clinical outcomes. The platform has shown excellent potential for the development of additional fungal MT-PCR assays targeting other organisms for different specimen types. Evaluation of the fungal MT-PCR on other types of clinical specimens is currently under way.
This work was supported in part by a Centre for Clinical Research Excellence grant (264625) from the National Health and Medical Research Council of Australia. A.L. is supported by an Australian Postgraduate Award.
Published ahead of print on 16 July 2008. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»